Trichostatin A

**Cat. No.:** HY-15144  
**CAS No.:** 58880-19-6  
**Molecular Formula:** C₁₇H₂₂N₂O₃  
**Molecular Weight:** 302.37  
**Target:** HDAC  
**Pathway:** Cell Cycle/DNA Damage; Epigenetics  
**Storage:**  
- **Powder**  
  -20°C: 3 years  
  4°C: 2 years  
- **In solvent**  
  -80°C: 6 months  
  -20°C: 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**  
DMSO: 25 mg/mL (82.68 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>3.3072 mL</td>
<td>16.5360 mL</td>
<td>33.0721 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.6614 mL</td>
<td>3.0372 mL</td>
<td>6.6144 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.3307 mL</td>
<td>1.6536 mL</td>
<td>3.072 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**  
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic

2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

**BIOLOGICAL ACTIVITY**

**Description**  
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC.

**IC₅₀ & Target**  
HDAC  
1.8 nM (IC₅₀)

**In Vitro**  
Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC₅₀ of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC₅₀ of 2.4±0.5 nM (range, 1.5-2.9 nM)[1]. Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not
increase Gs mRNA levels\(^2\). Trichostatin A (20-75 nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs\(^3\). In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity\(^4\).

### In Vivo

Trichostatin A (500 μg/kg, s.c.) pronounces antitumor activity without causing any measurable toxicity in doses of up to 5 mg/kg by s.c. injection, in randomized controlled efficacy studies using the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model\(^1\).

### Protocol

**Cell Assay**\(^3\)

Cells are cultured in a 96-well plate at 1×10\(^3\) cells per well with 100 μL complete DMEM in the presence or absence of a HDAC inhibitor Trichostatin A for 72 h. Cytotoxicity is measured by performing WST-8 assay using a CCK-8 cell proliferation kit. The 450 nm absorbance is measured with a microplate reader. All experiments are carried out in triplicate and 3 independent experiments are performed\(^3\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Administration**\(^1\)

Rats\(^1\)

Twelve rats are randomized to receive 500 μg/kg Trichostatin A in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection twice weekly for 4 weeks. In subsequent studies, 30 rats are randomized to receive Trichostatin A 500 μg/kg in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection daily for 4 weeks. Weekly tumor measurements, estimated tumor volumes, and body mass are recorded for each animal. Animals are sacrificed at the end of the 4-week study period; palpable tumors are resected and immediately snap-frozen in liquid nitrogen. Animals with tumors <2 cm in diameter or ulcerating tumors are withdrawn from study\(^1\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):9967-76.
- Theranostics. 2019 Apr 13;9(9):2424-2438.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES


\(^4\). Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898   Fax: 609-228-5909   E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA